In a powerful Member Blog  published on 1 August 2025, Johanna Ralston (World Obesity Federation) and Yvette Raphael (Advocates for the...

"When our leaders talk about integration, what do they really mean? It's hypocrisy when they tell us to use outpatient [clinics], when they know mobile clinics exist because of their criminalisation of our lives,” said Yvette Raphael, Executive Director of APHA, at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali.

The Lancet HIV’s July 2025 editorial shines a spotlight on a groundbreaking development in the fight against HIV: the FDA approval of injectable lenacapavir for pre-exposure prophylaxis (PrEP). This twice-yearly injectable, now approved for adults and adolescents over 35kg, represents a significant step forward in long-acting HIV prevention and offers hope for reaching populations previously left behind by traditional oral PrEP approaches.

At the 13th International AIDS Society Conference (IAS 2025) in Kigali, Rwanda, attendees voiced growing alarm over the devastating impact of U.S. federal funding cuts - driven by the Trump administration - on HIV prevention and care, especially for key populations like sex workers, people who use drugs, LGBTQ+ communities, and adolescent girls.

A powerful new Personal View published in The Lancet HIV features Advocacy for the Prevention of HIV and AIDS (APHA) Executive Director Yvette Raphael as a co-author. The article highlights the potential of long-acting lenacapavir to revolutionise HIV prevention - if global policy, funding, and delivery mechanisms rise to the challenge.

In a recent opinion piece by Yvette Raphael (APHA Executive Director) and Sibongile Tshabalala (TAC Chair) published in The Guardian, they warn that the withdrawal of U.S. HIV funding under President Trump has pushed South Africa's health system to a breaking point. Clinics - especially those serving transgender people, sex workers, and drug users - are struggling, HIV testing rates are falling, and frontline workers are losing jobs. Public trust is eroding, and services that

Co-founder and Executive Director for the Prevention of HIV in Africa, Yvette Raphael, received the Mani L. Bhaumik Breakthrough of the Year Award. This is for her pivotal role in advancing HIV prevention through the development and testing of Lenacapavir. She is one of three - and the only African, recognised as key role-players in advocating for access to adequate HIV care and treatment. Raphael elaborates.

APHA co-founder and chair person, Yvette Raphael, recently sat down with SciDev.net for a Q&A session where she emphaised the importance of inclusion of pregnant women and young girls in HIV trials, as well as healthcare and drug distribution programmes.

Today, Advocates for the Prevention of HIV in Africa (APHA) celebrates an extraordinary milestone as our co-founder and Executive Director, Yvette Raphael, receives the prestigious Mani L. Bhaumik Breakthrough of the Year Award for her pivotal role in advancing HIV prevention through the development and testing of Lenacapavir.

Yvette Raphael, co-founder and Executive Director at Apha, has been named as one of the three recipients of the Mani L. Bhaumik...

For decades, Africa’s HIV response has been heavily influenced by external donors and international health organisations. While these...

The fight against HIV has seen remarkable progress over the past two decades, with global initiatives like the U.S. President’s Emergency...

Watch Now

Image Source: Bhekisisa Pre-exposure prophylaxis (PrEP) is a preventive strategy involving a daily pill that combines two antiretroviral...

Image Source: Bhekisisa Yvette Raphael, a South African HIV activist diagnosed in 2000, has transformed her personal journey into a...

Source: Mail&Guardian Yvette Raphael, founder of Apha, sat down with the Bhekisisa Team at Mail&Guardian to discuss the implications of...